These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29302288)

  • 21. Use of direct oral anticoagulants for the prevention and treatment of thromboembolic disease in patients with reduced renal function: a short review of the clinical evidence.
    Willett KC; Morrill AM
    Ther Clin Risk Manag; 2017; 13():447-454. PubMed ID: 28435279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline Characteristics and 3-Year Outcome of Nonvalvular Atrial Fibrillation Patients Treated with the Four Direct Oral Anticoagulants (DOACs).
    Nemola G; Russi A; Cozzani G; Leo G; Vetrugno L; Sparasci FM; Parlati AL; Della Bella P; Montorfano M; Tresoldi M; Salerno A; Cera M; Mattiello P; Comi G; Maisano F; Zangrillo A; Gaspardone C; Melillo F; Margonato A; Godino C;
    Am J Cardiol; 2023 Nov; 206():125-131. PubMed ID: 37703678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
    Kimachi M; Furukawa TA; Kimachi K; Goto Y; Fukuma S; Fukuhara S
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011373. PubMed ID: 29105079
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
    Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of major bleeding risk in patients with non-valvular atrial fibrillation receiving direct oral anticoagulants in the real-world setting: a network meta-analysis.
    Deitelzweig S; Farmer C; Luo X; Li X; Vo L; Mardekian J; Fahrbach K; Ashaye A
    Curr Med Res Opin; 2018 Mar; 34(3):487-498. PubMed ID: 29188721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
    Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
    Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Risk of Postpolypectomy Bleeding in Patients Receiving Direct Oral Anticoagulants compared to Warfarin or Nonanticoagulation: A Systematic Review with Meta-Analysis.
    Ye HZ; Wang B; Zhou H; Gao JJ; Li ZW; Xu HW
    J Gastrointestin Liver Dis; 2022 Dec; 31(4):467-475. PubMed ID: 36535045
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series.
    DeCamillo D; Haymart B; Barnes GD
    J Thromb Thrombolysis; 2022 Apr; 53(3):601-606. PubMed ID: 34559367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Prevention of Thromboembolic Events Among Elderly Patients with Atrial Fibrillation.
    Kailas SD; Thambuluru SR
    Cureus; 2016 Oct; 8(10):e836. PubMed ID: 27900231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Utilization Pattern of Oral Anticoagulants in Patients with Atrial Fibrillation: A Nationwide Population-Based Study in Korea.
    Lee MY; Han S; Bang OY; On YK; Jang SW; Han S; Ryu J; Park YJ; Kang S; Suh HS; Kim YH
    Adv Ther; 2022 Jul; 39(7):3112-3130. PubMed ID: 35524839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pilot study on the probability of drug-drug interactions among direct oral anticoagulants (DOACs) and antiseizure medications (ASMs): a clinical perspective.
    Ranzato F; Roberti R; Deluca C; Carta M; Peretti A; Polo D; Perini F; Russo E; Di Gennaro G
    Neurol Sci; 2024 Jan; 45(1):277-288. PubMed ID: 37548755
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
    Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
    BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of Prescribing Practices and Outcomes Using Direct-acting Oral Anticoagulants After Cardiac Surgery.
    Kanaan DM; Cook BM; Kelly J; Malloy R
    Clin Ther; 2021 Jun; 43(6):e209-e216. PubMed ID: 34078556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bleeding with dabigatran, rivaroxaban, apixaban. No antidote, and little clinical experience.
    Prescrire Int; 2013 Jun; 22(139):155-9. PubMed ID: 23866358
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biopharmaceutics considerations for direct oral anticoagulants.
    de Andrade RP; Caldeira TG; Vasques BV; Morais Ruela AL; de Souza J
    Drug Dev Ind Pharm; 2021 Dec; 47(12):1881-1894. PubMed ID: 35377263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.